Cancer Genetics and Epigenetics, 2025, Vol.13, No.6, 300-309 http://medscipublisher.com/index.php/cge 308 References Adams S., Schmid P., Rugo H.S., Winer E.P., Loirat D., Awada A., Cescon D.W., Iwata H., Campone M., Nanda R., Hui R., Curigliano G., Toppmeyer D., O'Shaughnessy J., Loi S., Paluch-Shimon S., Tan A.R., Card D., Zhao J., Karantza V., and Cortés J., 2019, Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study, Annals of Oncology, 30(3): 397-404. https://doi.org/10.1093/annonc/mdy517 Binnewies M., Roberts E.W., Kersten K., Chan V., Fearon D.F., Merad M., Coussens L.M., Gabrilovich D.I., Ostrand-Rosenberg S., Hedrick C.C., Vonderheide R.H., Pittet M.J., Jain R.K., Zou W., Howcroft T.K., Woodhouse E.C., Weinberg R.A., and Krummel M.F., 2018, Understanding the tumor immune microenvironment (TIME) for effective therapy, Nature Medicine, 24(5): 541-550. https://doi.org/10.1038/s41591-018-0014-x Brahmer J.R., Lacchetti C., Schneider B.J., Atkins M.B., Brassil K.J., Caterino J.M., Chau I., Ernstoff M.S., Gardner J.M., Ginex P., Hallmeyer S., Holter Chakrabarty J., Leighl N.B., Mammen J.S., McDermott D.F., Naing A., Nastoupil L.J., Phillips T., Porter L.D., Puzanov I., Reichner C.A., Santomasso B.D., Seigel C., Spira A., Suarez-Almazor M.E., Wang Y., Weber J.S., Wolchok J.D., and Thompson J.A., 2018., Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: american society of clinical oncology clinical practice guideline, Journal of Clinical Oncology, 36(17): 1714-1768. https://doi.org/10.1200/JCO.2017.77.6385 Binnewies M., Roberts E.W., Kersten K., Chan V., Fearon D.F., Merad M., Coussens L.M., Gabrilovich D.I., Ostrand-Rosenberg S., Hedrick C.C., Vonderheide R.H., Pittet M.J., Jain R.K., Zou W., Howcroft T.K., Woodhouse E.C., Weinberg R.A., and Krummel M.F., 2018, Understanding the tumor immune microenvironment (TIME) for effective therapy, Nature Medicine., 24(5): 541-550. https://doi.org/10.1038/s41591-018-0014-x Chowell D., Morris L.G.T., Grigg C.M., Weber J.K., Samstein R.M., Makarov V., Kuo F., Kendall S.M., Requena D., Riaz N., Greenbaum B., Carroll J., Garon E., Hyman D.M., Zehir A., Solit D., Berger M., Zhou R., Rizvi N.A., and Chan T.A., 2018, Patient HLA class I genotype influences cancer response to checkpoint blockade immunotherapy, Science, 359(6375): 582-587. https://doi.org/10.1126/science.aao4572 Chung H.C., Ros W., Delord J.P., Perets R., Italiano A., Shapira-Frommer R., Manzuk L., Piha-Paul S.A., Xu L., Zeigenfuss S., Pruitt S.K., and Leary A., 2019, Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study, Journal of Clinical Oncology, 37(17): 1470-1478. https://doi.org/10.1200/JCO.18.01265 Cristescu R., Mogg R., Ayers M., Albright A., Murphy E., Yearley J., Sher X., Liu X.Q., Lu H., Nebozhyn M., Zhang C., Lunceford JK., Joe A., Cheng J., Webber AL., Ibrahim N., Plimack ER., Ott PA., Seiwert T.Y., Ribas A., McClanahan T.K., Tomassini J.E., Loboda A., and Kaufman D., 2018, Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy, Science, 362(6411): eaar3593. https://doi.org/10.1126/science.aar3593 Esteva A., Robicquet A., Ramsundar B., Kuleshov V., DePristo M., Chou K., Cui C., Corrado G., Thrun S., and Dean J., 2019, A guide to deep learning in healthcare, Nature Medicine, 25(1): 24-29. https://doi.org/10.1038/s41591-018-0316-z Fuchs C.S., Doi T., Jang R.W., Muro K., Satoh T., Machado M., Sun W., Jalal S.I., Shah M.A., Metges J.P., Garrido M., Golan T., Mandala M., Wainberg Z.A., Catenacci D.V., Ohtsu A., Shitara K., Geva R., Bleeker J., Ko A.H., Ku G., Philip P., Enzinger P.C., Bang Y.J., Levitan D., Wang J., Rosales M., Dalal RP., and Yoon H.H., 2018., Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial, JAMA Oncology, 4(5): e180013. https://doi.org/10.1001/jamaoncol.2018.0013 Gandhi L., Rodríguez-Abreu D., Gadgeel S., Esteban E., Felip E., De Angelis F., Domine M., Clingan P., Hochmair M.J., Powell S.F., Cheng S.Y., Bischoff H.G., Peled N., Grossi F., Jennens R.R., Reck M., Hui R., Garon E.B., Boyer M., Rubio-Viqueira B., Novello S., Kurata T., Gray J.E., Vida J., Wei Z., Yang J., Raftopoulos H., Pietanza M.C., and Garassino M.C., 2018, Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer, New England Journal of Medicine, 378(22): 2078-2092. https://doi.org/10.1056/NEJMoa1801005 Hellmann M.D., Paz-Ares L., Bernabe Caro R., Zurawski B., Kim S.W., Carcereny Costa E., Park K., Alexandru A., Lupinacci L., de la Mora Jimenez E., Sakai H., Albert I., Vergnenegre A., Peters S., Syrigos K., Barlesi F., Reck M., Borghaei H., Brahmer J.R., O'Byrne K.J., Geese W.J., Bhagavatheeswaran P., Rabindran S.K., Kasinathan R.S., Nathan F.E., and Ramalingam S.S., 2019, Nivolumab plus ipilimumab in advanced non-small-cell lung cancer, New England Journal of Medicine, 381(21): 2020-2031. https://doi.org/10.1056/NEJMoa1910231 Hodi F.S., O'Day S.J., McDermott D.F., Weber R.W., Sosman J.A., Haanen J.B., Gonzalez R., Robert C., Schadendorf D., Hassel J.C., Akerley W., van den Eertwegh A.J., Lutzky J., Lorigan P., Vaubel J.M., Linette GP., Hogg D., Ottensmeier C.H., LebbéC., Peschel C., Quirt I., Clark J.I., Wolchok J.D., Weber J.S., Tian J., Yellin M.J., Nichol G.M., Hoos A., and Urba WJ., 2010, Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine, 363(8): 711-723. https://doi.org/10.1056/NEJMoa1003466 Larkin J., Chiarion-Sileni V., Gonzalez R., Grob J.J., Rutkowski P., Lao C.D., Cowey C.L., Schadendorf D., Wagstaff J., Dummer R., Ferrucci P.F., Smylie M., Hogg D., Hill A., Márquez-Rodas I., Haanen J., Guidoboni M., Maio M., Schöffski P., Carlino M.S., LebbéC., McArthur G., Ascierto P.A., Daniels G.A., Long G.V., Bastholt L., Rizzo J.I., Balogh A., Moshyk A., Hodi F.S., and Wolchok J.D., 2019, Five-year survival with combined nivolumab and ipilimumab in advanced melanoma, New England Journal of Medicine, 381(16): 1535-1546. https://doi.org/10.1056/NEJMoa1910836
RkJQdWJsaXNoZXIy MjQ4ODYzNA==